Table 1.
Power to detect true-positive gene–medication interactions at CYP3A43 using 2 approaches. Gene–medication interactions (200 replicates) were simulated to be 6.2 mm Hg at 3 single nucleotide polymorphisms (SNPs) representing a range of minor allele frequencies (MAFs) (0.1 to 5.4 %)
| Interaction model | Med-diff approach | |||||||
|---|---|---|---|---|---|---|---|---|
| βInt | SEInt | 1DF PInt | 2DF PSNP, Int | βDiff | SEDiff | 1DF PDiff | 2DF PJoint | |
| chr7:99457518-A (0.1 % MAF) | ||||||||
| Mean | 12.35 | 15.42 | 4.3E-01 | 3.4E-01 | 11.82 | 15.29 | 4.2E-01 | 3.3E-01 |
| Min | −21.90 | 14.55 | 1.3E-03 | 2.9E-04 | −23.68 | 14.18 | 1.3E-03 | 6.1E-05 |
| Max | 51.85 | 16.69 | 1 | 9.9E-01 | 50.11 | 16.64 | 1 | 9.9E-01 |
| Median | 12.45 | 15.40 | 3.9E-01 | 2.4E-01 | 10.57 | 15.26 | 3.8E-01 | 2.3E-01 |
| Replicates P <0.05 of 141 converged | 12.1 % | 17.0 % | 13.5 % | 18.4 % | ||||
| chr7:99454482-G (0.8 % MAF) | ||||||||
| Mean | 5.20 | 8.61 | 4.5E-01 | 5.0E-01 | 4.10 | 8.25 | 4.3E-01 | 4.9E-01 |
| Min | −23.10 | 6.00 | 1.0E-03 | 2.3E-03 | −24.83 | 5.96 | 1.4E-03 | 3.9E-03 |
| Max | 29.80 | 12.37 | 1 | 1 | 30.15 | 12.51 | 9.9E-01 | 9.9E-01 |
| Median | 5.45 | 8.37 | 4.5E-01 | 5.1E-01 | 4.76 | 7.88 | 4.2E-01 | 5.2E-01 |
| Replicates P <0.05 of 190 converged | 7.9 % | 6.3 % | 9.5 % | 5.8 % | ||||
| chr7:99457605-C (5.4 % MAF) | ||||||||
| Mean | 5.11 | 2.60 | 1.3E-01 | 7.5E-02 | 4.85 | 2.63 | 1.5E-01 | 7.3E-02 |
| Min | −3.20 | 2.30 | 1.9E-06 | 8.2E-06 | −2.67 | 2.36 | 1.6E-06 | 2.8E-07 |
| Max | 13.44 | 2.92 | 9.8E-01 | 7.0E-01 | 13.59 | 3.02 | 9.9E-01 | 8.9E-01 |
| Median | 4.97 | 2.60 | 5.6E-02 | 2.2E-02 | 4.82 | 2.62 | 6.4E-02 | 2.0E-02 |
| Replicates P <0.05 of 200 converged | 47.5 % | 66.0 % | 43.5 % | 66.5 % | ||||
β Effect estimate, DF degrees of freedom, Diff Difference, Int interaction, Joint Joint estimates of both interaction and main genetic effects, MAF minor allele frequency, P p value, SE standard error